Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
One hundred and forty-six patients with advanced malignant disease were treated with 6 different dosage schedules of ifosfamide (IFX). Mesna was used as urothelial protector. With mesna, urothelial toxicity was moderate, and single doses of up to 7 g/m2 could be administered without intolerable urotoxicity. Leukopenia was the dose-limiting factor in this study. Unexpected pulmonary edema occurred in 3 patients. Therapeutic results were disappointing. A malignancy identified in this study that warrants further investigation with IFX and mesna, is malignant mesothelioma.
Falkson
C I
CI
Department of Medical Oncology, University of Pretoria, Republic of South Africa.
Falkson
H C
HC
Falkson
G
G
D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008623:Mercaptoethanol; D015080:Mesna / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D014570:Urologic Diseases / Q000139:chemically induced* / Q000517:prevention & control
D008623:Mercaptoethanol; D015080:Mesna; D007069:Ifosfamide